|Systematic (IUPAC) name|
|Mol. mass||342.743 g/mol|
|(what is this?)|
LGD-3303 is a drug which acts as a selective androgen receptor modulator, with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects. It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.
- Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. Journal of Pharmacology and Experimental Therapeutics. 2009 Feb;328(2):663-70. doi:10.1124/jpet.108.146811 PMID 19017848
- Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, Marschke K, Mais DE, Pedram B, Shen Y, van Oeveren A, Zhi L, López FJ, Meglasson MD. Combination Treatment With a Selective Androgen Receptor Modulator (SARM) and a Bisphosphonate Has Additive Effects in Osteopenic Female Rats. Journal of Bone and Mineral Research. 2008 Oct 10. PMID 18847323
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|